Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT307 (autologous TIL) in advanced solid tumors
NCT06397963Phase 1Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, Tumor-Infiltrating Lymphocytes (TILs), Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT307 in solid tumor, sponsored by Grit Biotechnology. Primary endpoint: Adverse Events at 3 years. Started Apr 2024; status: recruiting.
02
Drugs
GT307
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06397963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397963.